Group 1 - The core point of the article is the leadership change at Xibei, with former CEO Dong Junyi returning to the position after the resignation of Jia Guolong due to significant business volume decline [4][5]. - Xibei has announced that due to a substantial decrease in business volume, many headquarters employees will need to be on standby or leave the company [5][7]. - The number of employees at Xibei's headquarters, originally over 500, is expected to drop to around 200 after the layoffs [7]. Group 2 - ByteDance has initiated its largest-ever intern recruitment drive, aiming to hire over 7,000 interns globally, with a focus on R&D, product, and AI fields [6][8]. - The recruitment plan includes over 4,800 offers for R&D positions, accounting for more than 60% of the total [8]. - The overall conversion rate for these intern positions is expected to exceed 50% [8]. Group 3 - The article mentions that the U.S. stock market indices collectively fell, with the Nasdaq down 1.59% and the S&P 500 down 1.33% [11]. - International crude oil futures saw a significant increase, with WTI crude oil futures rising 12.21% to $90.9 per barrel, marking a weekly increase of over 35% [11]. Group 4 - The Ministry of Commerce reported that the cross-border e-commerce import and export scale reached 2.75 trillion yuan [14]. - The revenue share of Chinese online dramas in the global market has reached 90%, with app downloads accounting for 80% globally [15]. Group 5 - Toshiba is restructuring its substantial debt with the goal of returning to the public market by the fiscal year 2028 [17]. - Pfizer China announced the approval of a new GLP-1 receptor agonist for long-term weight management in adults [18]. Group 6 - New Hope reported a decline in sales revenue from commodity pigs, amounting to 1.327 billion yuan, with a year-on-year decrease of 7.42% [20]. - Lao Fengxiang's net profit for the fiscal year 2025 was reported at 1.755 billion yuan, down 9.99% year-on-year [21]. Group 7 - Wanbangde expects a net profit growth of 985.40% year-on-year for the first quarter of 2026, driven by a strategic shift from generic to innovative drugs [22]. - Quince is in talks for financing that could double its valuation to over $10 billion [23].